Clinical trial NCT01199471: Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane
Official title: A Multi-center Registry to Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia, General
Keywords: Sevoflurane
Physician's Practice Patterns
Economics, Pharmaceutical
Chinese
Lead sponsor: Abbott
Sponsor class: INDUSTRY
Collaborators: name: Rundo-Cronova International Pharmaceuticals Research & Development Co., Ltd.
First posted: 2010-09-13
Enrollment: 4000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Chinese patients undergoing surgery requiring general anesthesia with endotracheal intubation or laryngeal mask airway

Brief summary: This registry is primarily aiming to demonstrate the correlation between good practices of anesthesiologists and patient related outcomes including decreased overall anesthesia cost. The investigators would also like to demonstrate how the training background, and experience in inhalational anesthesia of the anesthesiologist influence their daily practice. At the end of the registry, the investigators would be able to demonstrate the influence of different practice pattern on patient related outcomes between the sites at which anesthesiologists follow modern anesthesiology practice based on their training/experience background and at which anesthesiologists do not follow same type of practice due to lack of their inhalational anesthesia training/experience.


Eligibility criteria: Inclusion Criteria:

1. ASA (American Society of Anesthesiologists) physical status (a requirement of the patient's physical status): I to III
2. Age from 18 to 70 years
3. Surgery requiring general anesthesia with endotracheal intubation or laryngeal mask airway.

Exclusion Criteria:

1. History of significant cardiovascular, pulmonary, renal, hepatic or central nervous system disease or muscle disease.
2. Hypersensitivity or unusual response to any halogenated anesthetics.
3. Personal or familial history of malignant hyperthermia.
4. Female patients either pregnant or breast feeding.
5. General anesthesia is administered with total intravenous anesthesia (TIVA) of propofol.

Primary outcomes:
measure: Anesthesiologist Satisfaction With the Anesthesia Recorded at the End of the Operation Using a Numeric Analog Scale (NAS)
timeFrame: Within 24 hours
measure: Patient Satisfaction With the Anesthesia Recorded at the End of the Operation Using a Numeric Analog Scale (NAS)
timeFrame: Within 24 hours
Secondary outcomes:
measure: Time to Loss of Consciousness of Patients Administered Anesthesia
timeFrame: Up to 10 minutes
measure: Time to Intubation of Patients
timeFrame: Up to 10 minutes
measure: Time to Eye Opening of Patients
timeFrame: Every minute after cessation of anesthesia until the patient opened his/her eyes
measure: Time to Extubation of Patients
timeFrame: Every minute after cessation of anesthesia until the patient was extubated
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Site Reference ID/Investigator# 43073
state: Guangdong
city: Guangzhou
country: China
facility: Site Reference ID/Investigator# 43072
state: Guangdong
city: Guangzhou
country: China
facility: Site Reference ID/Investigator# 46407
state: Guangdong
city: Guangzhou
country: China
facility: Site Reference ID/Investigator# 43076
state: Guangdong
city: Guangzhou
country: China
facility: Site Reference ID/Investigator# 43077
state: Guangdong
city: Harbin
country: China
facility: Site Reference ID/Investigator# 43066
state: Heilongjiang
city: Harbin
country: China
facility: Site Reference ID/Investigator# 43068
state: Heilongjiang
city: Wuhan
country: China
facility: Site Reference ID/Investigator# 43071
state: Hubei
city: Wuhan
country: China
facility: Site Reference ID/Investigator# 43070
state: Hubei
city: Chengdu
country: China
facility: Site Reference ID/Investigator# 43065
state: Sichuan
city: Chengdu
country: China
facility: Site Reference ID/Investigator# 43064
state: Sichuan
city: Beijing
country: China
facility: Site Reference ID/Investigator# 43056
city: Beijing
country: China
facility: Site Reference ID/Investigator# 43060
city: Beijing
country: China
facility: Site Reference ID/Investigator# 46406
city: Beijing
country: China
facility: Site Reference ID/Investigator# 43058
city: Beijing
country: China
facility: Site Reference ID/Investigator# 44382
city: Beijing
country: China
facility: Site Reference ID/Investigator# 43059
city: Beijing
country: China
facility: Site Reference ID/Investigator# 43062
city: Beijing
country: China
facility: Site Reference ID/Investigator# 43063
city: Beijing
country: China
facility: Site Reference ID/Investigator# 43061
city: Beining
country: China
facility: Site Reference ID/Investigator# 43057
city: Daqing
country: China
facility: Site Reference ID/Investigator# 44384
city: Guangzhou
country: China
facility: Site Reference ID/Investigator# 44383
city: Guangzhou
country: China
facility: Site Reference ID/Investigator# 43074
city: Harbin
country: China
facility: Site Reference ID/Investigator# 43067
city: Jiangsu
country: China
facility: Site Reference ID/Investigator# 43051
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 43015
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 43017
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 41554
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 46405
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 43012
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 43014
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 43011
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 43018
city: Shanghai
country: China
facility: Site Reference ID/Investigator# 46404
city: Wuhan, Hubei
country: China
facility: Site Reference ID/Investigator# 43069
city: Zhejiang
country: China
facility: Site Reference ID/Investigator# 43052
city: Zhejiang
country: China
facility: Site Reference ID/Investigator# 43053
city: Zhejiang
country: China
facility: Site Reference ID/Investigator# 43054
city: Zhejiang
country: China
facility: Site Reference ID/Investigator# 43055
Study officials:
affiliation: Abbott
name: Yue Kang, MD
role: STUDY_DIRECTOR
References: